Fibroblast growth factor family aberrations in cancers: Clinical and molecular characteristics

Cell Cycle

Volumn 14, Issue 13, 2015, Pages 2121-2128

  Parish, A ^a   Schwaederle, M ^a   Daniels, G ^a,b   Piccioni, D ^a,b   Fanta, P ^a,b   Schwab, R ^a,b   Shimabukuro, K ^a,b   Parker, B A ^a,b   Helsten, T ^a,b   Kurzrock, R ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; FGF; FGFR; Profiling; Sequencing

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 12; FIBROBLAST GROWTH FACTOR 14; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 6; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KERATINOCYTE GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; METASTASIS; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; AGED; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AGED; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84943737092     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1041691     Document Type: Article

References (32)

1. Brooks AN, Kilgour E, Smith PD. Molecular Pathways. Fibroblast growth factor signaling. a new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18(7): 1855-62; PMID: 22388515; http://dx. doi. org/10. 1158/1078-0432. CCR-11-0699.
2. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway. opportunities for targeted therapies in solid tumors. Ann Oncol 2014; 25(3): 552-63; PMID: 24265351; http://dx. doi. org/10. 1093/annonc/mdt419.
3. Turner N, Grose R. Fibroblast growth factor signaling. from development to cancer. Nat Rev Cancer 2010; 10: 116-29; PMID: 20094046; http://dx. doi. org/10. 1038/nrc2780.
4. Nie X, Luukko K, Kettunen P. FGF signaling in craniofacial development and developmental disorders. Oral Dis 2006; 12(2): 102-11; PMID: 16476029; http://dx. doi. org/10. 1111/j. 1601-0825. 2005. 01176. x.
5. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. the complete mammalian FGF family. J Biol Chem 2006; 281: 15694-700; PMID: 16597617; http://dx. doi. org/10. 1074/jbc. M601252200.
6. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-78; PMID: 15863032; http://dx. doi. org/10. 1016/j. cytogfr. 2005. 01. 004.
7. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213; PMID: 21711248; http://dx. doi. org/10. 1042/BJ20101603.
8. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. J Canc Res 2000; 60(15): 4245-50.
9. Itoh N, Ornitz D. Evolution of the FGF and FGFR gene families. Trends Genet 2004; 20: 563-9;; PMID: 15475116; http://dx. doi. org/10. 1016/j. tig. 2004. 08. 007.
10. Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013; 57(4): 1407-15; PMID: 22890726; http://dx. doi. org/10. 1002/hep. 25956.
11. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, Bianciotto M et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 2013; 23(4): 477-88; PMID: 23597562; http://dx. doi. org/10. 1016/j. ccr. 2013. 02. 019.
12. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF. inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17(19): 6130-9; PMID: 21953501; http://dx. doi. org/10. 1158/1078-0432. CCR-11-0659.
13. Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013; 340: 97-103; PMID: 23856031; http://dx. doi. org/10. 1016/j. canlet. 2013. 07. 007.
14. Soria J, DeBraud F, Bahleda R, Adamo B, Andre F, Dientsmann R, Delmonte A, Cereda R, Isaacson J, Litten J et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 2014; 25: 2244-51; PMID: 25193991; http://dx. doi. org/10. 1093/annonc/mdu390.
15. Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R, Michaelson MD. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol 2013; 73: 181-9; PMID: 24190702; http://dx. doi. org/10. 1007/s00280-013-2339-y.
16. Capdevila J, Dienstmann R, Adamo B, Cereda R, Litten J, Collin J, Legrand F, Robert R, Saba C, De Braud FGM et al. Prolonged anti-tumor activity of lucitanib in advanced thyroid cancer. Ann Oncol 2014; 25(suppl 4): iv340-56.
17. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ et al. AZD4547; an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72(8): 2045-56; PMID: 22369928; http://dx. doi. org/10. 1158/0008-5472. CAN-11-3034.
18. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010; 70(10): 4151-62; PMID: 20460524; http://dx. doi. org/10. 1158/0008-5472. CAN-09-4479.
19. Elsheikh ES, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, Reis-Filho JS. FGFR1 amplification in breast carcinomas. a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9 (2): R23; PMID: 17397528; http://dx. doi. org/10. 1186/bcr1665.
20. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002; 2: 301-14; PMID: 12398894; http://dx. doi. org/10. 1016/S1535-6108(02)00150-2.
21. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085-94; PMID: 20179196; http://dx. doi. org/10. 1158/0008-5472. CAN-09-3746.
22. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008; 10: 847-56; PMID: 18670643; http://dx. doi. org/10. 1593/neo. 08450.
23. Weiss J, Sos M, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2(62): 62ra93; PMID: 21160078; http://dx. doi. org/10. 1126/scitranslmed. 3001451.
24. Koziczak M, Holbro T, Hynes N. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004; 23: 3501-8; PMID: 15116089; http://dx. doi. org/10. 1038/sj. onc. 1207331.
25. Hynes N, Dey J. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 2010; 70: 5199-202; PMID: 20570901; http://dx. doi. org/10. 1158/0008-5472. CAN-10-0918.
26. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008; 14: 8000-9; PMID: 19088016; http://dx. doi. org/10. 1158/1078-0432. CCR-08-0975.
27. Singh D, Chan J, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231-5; PMID: 22837387; http://dx. doi. org/10. 1126/science. 1220834.
28. Guancial E, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz F, Park R, O'Brein R, Hirsch M et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med 2014; 3: 835-44; PMID: 24846059; http://dx. doi. org/10. 1002/cam4. 262.
29. Foldynova-Trantirkova S, Wilcox W, Krejci P. Sixteen years and counting. The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat 2011; 33: 29-41; PMID: 22045636; http://dx. doi. org/10. 1002/humu. 21636.
30. Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker B, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and coamplification network. Oncotarget 2015; 6(5): 3033-42; PMID: 25596748.
31. Simon R, Bürger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998; 185: 345-51; PMID: 9828832; http://dx. doi. org/10. 1002/(SICI)1096-9896(199808)185: 4%3c 345:: AID-PATH109%3e3. 0. CO; 2-0.
32. Dellas A, Torhorst J, Jiang F, Proffitt J, Schultheiss E, Holzgreve W, Sauter G, Mihatsch MJ, Moch H. Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization. Cancer Res 1999; 59: 3475-9; PMID: 10416613.